Table 3.
Variables associated with an increased risk of TFN results with CEDMs, variables associated with a greater probability of being TPs with CEDMs and how each one affected the probability of a malignant lesion showing enhancement with CEDMs.
| Characteristic | TP (n) | TFN (n) | Univariate analysis |
Binary logistic regression |
BCs showing enhancement with CEDM (95% CI) | TFN-ir/TP-gp | |||
|---|---|---|---|---|---|---|---|---|---|
| p-value | p-value | Odds Ratio (OR) 95% CI | |||||||
| Radiological features | Breast density | BI-RADS A + BI-RADS B |
208 | 9 | – | ||||
| BI-RADS C + BI-RADS D |
109 | 4 | – | ||||||
| BPE | Minimal + Mild | 247 | 10 | – | |||||
| Moderate + Marked | 109 | 3 | – | ||||||
| Index lesion on CI | Developing Asymmetry | 3 | 0 | – | |||||
| Architectural distortion | 9 | 0 | – | ||||||
| Microcalcifications | 41 | 7 | <0.0001 | 0.0004 | 7.8537 (2.5150–24.5252) | 85.42% (72.24%–93.93%) | TFN-ir | ||
| DM/DBT Mass | 2 | 0 | – | ||||||
| US and DM/DBT Mass | 109 | 2 | – | ||||||
| US mass | 153 | 4 | – | ||||||
| All US MassΦ | 262 | 6 | 0.0010 | 0.0029 | 0.1799 (0.0582–0.5562) | 97.76% (95.19%–99.17%) | TP-gp | ||
| All DM/DBT MassΣ | 111 | 2 | – | ||||||
| Histological and molecular characteristic | Extension of the disease | Unifocal | 184 | 13 | 0.0012 | 0.0396 | 19.5366 (1.1512–331.5516) | 93,4% (88.98%–96.44%) | TFN-ir |
| Multifocal | 89 | 0 | 0.0234 | – | 100.00% (95.94%–100.00%) | TP-gp | |||
| Multicentric | 44 | 0 | – | ||||||
| Molecular Subtypes | Luminal A | 85 | 2 | – | |||||
| Luminal B HER2- | 155 | 1 | 0.0034 | 0.0197 | 0.0871 (0.0112–0.6778) | 99.36% (96.48%–99.98%) | TP-gp | ||
| Luminal B HER2+ | 30 | 1 | – | ||||||
| HER2 Enriched | 9 | 1 | – | ||||||
| Triple Negative | 17 | 0 | – | ||||||
| Not classifiable | 21 | 8 | <0.0001 | <0.0001 | 22.5524 (6.7801–75.0148) | 72.41% (52.76%–87.27%) | TFN-ir | ||
| Histology | DCIS | 21 | 8 | <0.0001 | <0.0001 | 22.5524 (6.7801–75.0148) | 72.41% (52.76%–87.27%) | TFN-ir | |
| IDC∗ | 199 | 4 | 0.0373 | 0.0293 | 0.2635 (0.0794–0.8747) | 98.03% (95.03%–99.46%) | TP-gp | ||
| ILC | 36 | 0 | – | ||||||
| Other invasive histotypes | 61 | 1 | – | ||||||
| Dimensions at pathology | ≥ 10 mm | 224 | 4 | 0.0043 | 0.0059 | 0.1845 (0.0554–0.6141) | 98.25% (95.57%–99.52%) | TP-gp | |
| < 10 mm | 93 | 9 | 0.0043 | 0.0059 | 5.4194 (1.6284–18.0356) | 91.18% (83.91%–95.89%) | TFN-ir | ||
| Histological Grade | G1 | 74 | 3 | – | |||||
| G2 | 150 | 9 | – | ||||||
| G3 | 93 | 1 | – | ||||||
| Ki67 | Ki67 ≥ 20% | 209 | 2 | – | |||||
| Ki67 < 20% | 87 | 3 | – | ||||||
| Clinical and demographic variables | Age | ≥50 | 235 | 8 | – | ||||
| <50 | 82 | 5 | – | ||||||
| Index lesion Palpability | Yes | 121 | 3 | – | |||||
| No | 196 | 10 | – | ||||||
| Personal History of BC | Yes | 36 | 3 | – | |||||
| No | 281 | 10 | – | ||||||